| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Acat2; ACTL;;ACAT2 |
| WB Predicted band size | Calculated MW: 41 kDa ; Observed MW: 38 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human ACAT2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于ACAT2抗体的3篇参考文献概览(虚构示例，仅供参考)：
1. **文献名称**：*Role of ACAT2 in cholesterol absorption: Insights from gene knockout mice*
**作者**：Lee, S. et al.
**摘要**：通过使用特异性ACAT2抗体检测小鼠肠道组织中的酶表达，研究发现ACAT2基因敲除小鼠的胆固醇酯化能力显著下降，提示其在肠道胆固醇吸收中的关键作用。
2. **文献名称**：*ACAT2 inhibition reduces atherosclerosis in a murine model*
**作者**：Bhattacharya, D. et al.
**摘要**：利用多克隆ACAT2抗体进行免疫印迹和免疫组化分析，发现抑制ACAT2可减少动脉粥样硬化斑块中胆固醇酯的积累，为靶向治疗提供了实验依据。
3. **文献名称**：*Tissue-specific expression of ACAT2 in metabolic syndrome*
**作者**：Matsuda, K. et al.
**摘要**：通过Western blot和免疫荧光技术(使用ACAT2单克隆抗体)，揭示了ACAT2在肝脏和小肠中的差异表达，其表达水平与高脂饮食诱导的代谢紊乱相关。
---
⚠️ **注意**：以上文献信息为示例，实际引用请通过PubMed或学术数据库检索真实文献(可尝试关键词：ACAT2 antibody + cholesterol/atherosclerosis/metabolism)。若需要具体文献协助，请提供更多背景信息。
ACAT2 (acyl-CoA:cholesterol acyltransferase 2) is a key enzyme in cholesterol metabolism, primarily expressed in the intestine and liver. It catalyzes the esterification of free cholesterol into cholesteryl esters, a critical step for packaging dietary and hepatic cholesterol into apolipoprotein B-containing lipoproteins (e.g., chylomicrons and VLDL). Unlike the ubiquitously expressed ACAT1. ACAT2 shows tissue-specific activity and is considered a potential therapeutic target for atherosclerosis due to its role in promoting cholesterol absorption and lipoprotein secretion.
ACAT2 antibodies are immunological tools developed to study the enzyme's expression, localization, and function. These antibodies enable researchers to detect ACAT2 protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Studies using ACAT2 antibodies have revealed its predominant localization in the endoplasmic reticulum of enterocytes and hepatocytes. Research highlights its association with cardiovascular diseases, as ACAT2-deficient mice show reduced atherosclerosis progression despite unchanged plasma cholesterol levels, suggesting its direct impact on arterial cholesterol accumulation.
Pharmaceutical interest in ACAT2 inhibitors for treating dyslipidemia and atherosclerosis has driven antibody development for preclinical validation. However, clinical trials of ACAT inhibitors have shown mixed results, emphasizing the need for deeper mechanistic studies facilitated by specific antibodies. Current applications include investigating ACAT2's regulatory mechanisms, its interplay with lipid metabolism pathways, and its role in metabolic disorders beyond cardiovascular disease.
×
